NYSE:HAE Haemonetics (HAE) Stock Price, News & Analysis $79.00 -1.38 (-1.72%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Haemonetics Stock (NYSE:HAE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Haemonetics alerts:Sign Up Key Stats Today's Range$78.13▼$80.3150-Day Range$72.45▼$91.4252-Week Range$70.74▼$97.97Volume867,256 shsAverage Volume545,916 shsMarket Capitalization$4.03 billionP/E Ratio34.50Dividend YieldN/APrice Target$106.14Consensus RatingModerate Buy Company OverviewHaemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Read More… Kamala’s Dirty Election Move… Revealed (Ad)According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. Haemonetics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks99th Percentile Overall ScoreHAE MarketRank™: Haemonetics scored higher than 99% of companies evaluated by MarketBeat, and ranked 9th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingHaemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageHaemonetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Haemonetics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth14.66% Earnings GrowthEarnings for Haemonetics are expected to grow by 14.66% in the coming year, from $4.57 to $5.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 34.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 34.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.01.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 1.19. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Haemonetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.67% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Haemonetics has recently decreased by 11.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-0.54 Percentage of Shares Shorted10.67% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Haemonetics has recently decreased by 11.33%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.10 News SentimentHaemonetics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Haemonetics this week, compared to 5 articles on an average week.Search Interest6 people have searched for HAE on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $585,279.00 in company stock.Percentage Held by InsidersOnly 1.80% of the stock of Haemonetics is held by insiders.Percentage Held by Institutions99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Haemonetics' insider trading history. Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Email Address HAE Stock News HeadlinesBuy Rating Affirmed for Haemonetics with Promising Growth in Hospital Segment and Strong Plasma Market PositionSeptember 24, 2024 | markets.businessinsider.comTaking A Look At Haemonetics Corporation's (NYSE:HAE) ROESeptember 24, 2024 | finance.yahoo.comNext Week Elon Could Trigger a Boom in this Sub-$3 Stock Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world… October 2, 2024 | InvestorPlace (Ad)Haemonetics (NYSE:HAE) Receives Outperform Rating from Barrington ResearchSeptember 24, 2024 | americanbankingnews.comHaemonetics Technology Chief to ExitSeptember 16, 2024 | marketwatch.comCL King Initiates Coverage of Haemonetics (HAE) with Buy RecommendationSeptember 14, 2024 | nasdaq.comB of A Securities Initiates Coverage of Haemonetics (HAE) with Neutral RecommendationSeptember 12, 2024 | msn.comBTIG Initiates Coverage of Haemonetics (HAE) with Buy RecommendationSeptember 10, 2024 | msn.comSee More Headlines HAE Stock Analysis - Frequently Asked Questions How have HAE shares performed this year? Haemonetics' stock was trading at $85.51 at the start of the year. Since then, HAE shares have decreased by 7.6% and is now trading at $79.00. View the best growth stocks for 2024 here. How were Haemonetics' earnings last quarter? Haemonetics Co. (NYSE:HAE) posted its quarterly earnings data on Thursday, August, 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by $0.01. The company's revenue was up 8.0% on a year-over-year basis. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN) and Company Calendar Last Earnings8/08/2024Today10/01/2024Next Earnings (Estimated)11/07/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNYSE:HAE CUSIP40502410 CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,657Year Founded1971Price Target and Rating Average Stock Price Target$106.14 High Stock Price Target$125.00 Low Stock Price Target$85.00 Potential Upside/Downside+34.4%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$2.29 Trailing P/E Ratio34.50 Forward P/E Ratio17.29 P/E Growth1.19Net Income$117.56 million Net Margins8.61% Pretax Margin11.02% Return on Equity21.86% Return on Assets9.04% Debt Debt-to-Equity Ratio1.35 Current Ratio3.76 Quick Ratio2.33 Sales & Book Value Annual Sales$1.33 billion Price / Sales3.02 Cash Flow$6.26 per share Price / Cash Flow12.62 Book Value$18.90 per share Price / Book4.18Miscellaneous Outstanding Shares50,953,000Free Float50,036,000Market Cap$4.03 billion OptionableOptionable Beta0.30 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NYSE:HAE) was last updated on 10/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.